4.6 Article

Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease

Journal

ACTA NEUROPATHOLOGICA COMMUNICATIONS
Volume 4, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s40478-016-0317-4

Keywords

Tau; Fyn; SH3; Alzheimer's disease; PXXP motif; Phosphorylation

Categories

Funding

  1. Alzheimer's Research UK
  2. Croucher Foundation
  3. BBSRC
  4. Eli Lilly
  5. Alzheimers Research UK [ART-TRF2011-2, ART-PhD2011-15] Funding Source: researchfish

Ask authors/readers for more resources

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by neuropathological deposits of amyloid plaques and neurofibrillary tangles comprised of beta-amyloid and tau protein, respectively. In AD, tau becomes abnormally phosphorylated and aggregates to form intracellular deposits. However, the mechanisms by which tau exerts neurotoxicity in disease remain unclear. Recent studies have suggested that the presence of tau at synapses may indicate a role in neuronal signalling, which could be disrupted in pathological conditions. The non-receptor-associated tyrosine kinase fyn is located at the dendrite in neurons, where it was recently shown to interact with tau to stabilise receptor complexes at the post-synaptic density. Fyn also co-localises with tau in a proportion of neurons containing tau tangles in AD and fyn is also a tau kinase. Hence, tau-fyn interactions could play a pathogenic role in AD. Here we report the identification of critical proline residues, Pro213, Pro216, and Pro219, located within the fifth and sixth Pro-X-X-Pro motifs in the proline-rich region of tau, that are important for its binding to fyn. These residues in tau are flanked by numerous phosphorylation sites and therefore we investigated the relationship between fyn and the degree of tau phosphorylation in human post-mortem brain tissue. We found no difference in the amount of fyn present in control and AD brain. Notably, however, there was a significant correlation between fyn and phosphorylated tau at specific phospho-epitopes in control, but not in AD brain. Our results suggest that the pathological mechanisms underlying AD, that result in increased tau phosphorylation, may disrupt the physiological relationship between tau phosphorylation and fyn.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Pharmacology & Pharmacy

Considerations for future tau-targeted therapeutics: can they deliver?

Wendy Noble, Maria Jimenez-Sanchez, Beatriz G. Perez-Nievas, Diane P. Hanger

EXPERT OPINION ON DRUG DISCOVERY (2020)

Editorial Material Neurosciences

Editorial: Tau Propagation Mechanisms: Cell Models, Animal Models, and Beyond

Yumiko Motoi, Diane P. Hanger, Masato Hasegawa

FRONTIERS IN NEUROSCIENCE (2020)

Article Biochemistry & Molecular Biology

Tau accumulates in Crohn's disease gut

Alice Prigent, Guillaume Chapelet, Adrien De Guilliem de Lataillade, Thibauld Outlier, Emilie Durieu, Arnaud Bourreille, Emilie Duchalais, Kevin Hardonniere, Michel Neunlist, Wendy Noble, Saadia Kercline-Romer, Pascal Derkinderen, Malvyne Rolli-Derkinderen

FASEB JOURNAL (2020)

Article Neurosciences

Disruption of endoplasmic reticulum-mitochondria tethering proteins in post-mortem Alzheimer's disease brain

Dawn H. W. Lau, Sebastien Paillusson, Naomi Hartopp, Huzefa Rupawala, Gabor M. Morotz, Patricia Gomez-Suaga, Jenny Greig, Claire Troakes, Wendy Noble, Christopher C. J. Miller

NEUROBIOLOGY OF DISEASE (2020)

Review Clinical Neurology

Astrocytes in Tauopathies

Matthew J. Reid, Paula Beltran-Lobo, Louisa Johnson, Beatriz Gomez Perez-Nievas, Wendy Noble

FRONTIERS IN NEUROLOGY (2020)

Review Biochemistry & Molecular Biology

Tau in the gut, does it really matter?

Pascal Derkinderen, Malvyne Rolli-Derkinderen, Guillaume Chapelet, Michel Neunlist, Wendy Noble

Summary: The enteric nervous system, often referred to as the 'second brain', shares many features with the central nervous system and may be susceptible to neurodegenerative diseases similar to those affecting the brain. Current studies focus on the expression and phosphorylation pattern of tau protein in the enteric nervous system, exploring the potential occurrence of 'enteric tauopathies'.

JOURNAL OF NEUROCHEMISTRY (2021)

Article Biochemistry & Molecular Biology

Oxysterols present in Alzheimer's disease brain induce synaptotoxicity by activating astrocytes: A major role for lipocalin-2

Erica Staurenghi, Valentina Cerrato, Paola Gamba, Gabriella Testa, Serena Giannelli, Valerio Leoni, Claudio Caccia, Annalisa Buffo, Wendy Noble, Beatriz Gomez Perez-Nievas, Gabriella Leonarduzzi

Summary: Among the brain hallmarks of Alzheimer's disease, reactive astrocytes are correlated with neuronal loss and cognitive deficits, while alterations in brain cholesterol metabolism contribute to AD pathogenesis. Oxysterols in AD brains induce astrocyte reactivity and the release of mediators that impact neuronal health and synapses, with lipocalin-2 playing a key role in mediating the synaptotoxic effect of oxysterol-treated astrocytes.

REDOX BIOLOGY (2021)

Article Cell Biology

Disruption of ER-mitochondria tethering and signalling in C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia

Patricia Gomez-Suaga, Gabor M. Morotz, Andrea Markovinovic, Sandra M. Martin-Guerrero, Elisavet Preza, Natalia Arias, Keith Mayl, Afra Aabdien, Vesela Gesheva, Agnes Nishimura, Ambra Annibali, Younbok Lee, Jacqueline C. Mitchell, Selina Wray, Christopher Shaw, Wendy Noble, Christopher C. J. Miller

Summary: This study reveals that hexanucieotide repeat expansions in C9orf72 disrupt the ER-mitochondria signalling and VAPB-PTPIP51 tethers, leading to neurotoxicity. The interaction between VAPB-PTPIP51 is disrupted by neurotoxic DPRs, potentially involving the activation of GSK3β. Furthermore, these DPRs also disrupt the delivery of Ca2+ from ER stores to mitochondria, which is a primary function of the VAPB-PTPIP51 tethers. These findings identify a new molecular target for mutant C9orf72-mediated toxicity.

AGING CELL (2022)

Article Immunology

Astrocytic C-X-C motif chemokine ligand-1 mediates β-amyloid-induced synaptotoxicity

Beatriz G. Perez-Nievas, Louisa Johnson, Paula Beltran-Lobo, Martina M. Hughes, Luciana Gammallieri, Francesca Tarsitano, Monika A. Myszczynska, Irina Vazquez-Villasenor, Maria Jimenez-Sanchez, Claire Troakes, Stephen B. Wharton, Laura Ferraiuolo, Wendy Noble

Summary: The pathological interactions between beta-amyloid (A beta) and tau contribute to synapse loss and cognitive decline in Alzheimer's disease (AD). Reactive astrocytes play a prominent role in AD brain and exacerbate the synaptotoxic effects of A beta through the interaction of astrocytic CXCL1 and neuronal CXCR2 receptors, suggesting a potential novel therapeutic target.

JOURNAL OF NEUROINFLAMMATION (2021)

Article Biochemistry & Molecular Biology

The Disease Associated Tau35 Fragment has an Increased Propensity to Aggregate Compared to Full-Length Tau

Chen Lyu, Stefano Da Vela, Youssra Al-Hilaly, Karen E. Marshall, Richard Thorogate, Dmitri Svergun, Louise C. Serpell, Annalisa Pastore, Diane P. Hanger

Summary: Tau35 is a truncated form of tau found in human brain in certain tauopathies, and its expression in mice recapitulates key features of human disease including increased tau phosphorylation and cognitive/motor dysfunction. Structural characterization revealed that Tau35 exhibits higher rigidity and a higher propensity to aggregate compared to longer tau isoforms 2N3R and 2N4R. Tau35 aggregates are morphologically similar to previously reported tau fibrils but more densely packed, shedding light on their potentially damaging role in tauopathies.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

Article Clinical Neurology

Investigating key factors underlying neurodegeneration linked to alpha-synuclein spread

Cindy C. C. Pang, Maja H. Sorensen, Krit Lee, Kelvin C. Luk, John Q. Trojanowski, Virginia M. Y. Lee, Wendy Noble, Raymond C. C. Chang

Summary: This study investigates the role of pathological alpha-synuclein in Parkinson's disease. The results suggest that spread/replication of pathological aSyn may not be sufficient to induce neurodegenerative changes. Instead, oxidative stress responses and aSyn accumulation are associated with other Parkinson's disease-associated abnormalities and cognitive dysfunction.

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2022)

Review Biochemistry & Molecular Biology

Astrocyte adaptation in Alzheimer's disease: a focus on astrocytic P2X7R

Paula Beltran-Lobo, Matthew J. Reid, Maria Jimenez-Sanchez, Alexei Verkhratsky, Beatriz G. Perez-Nievas, Wendy Noble

Summary: Astrocytes play important roles in maintaining the balance and defense of the central nervous system. In Alzheimer's disease, astrocytes undergo various changes and are closely associated with abnormal protein aggregates. This review focuses on the P2X7 receptor and its contribution to altered astrocyte functions in Alzheimer's disease. Animal studies have shown that targeting P2X7 receptor can improve cognitive and synaptic impairments in models of the disease.

ESSAYS IN BIOCHEMISTRY (2023)

Review Clinical Neurology

Artificial intelligence for neurodegenerative experimental models

Sarah J. Marzi, Brian M. Schilder, Alexi Nott, Carlo Sala Frigerio, Sandrine Willaime-Morawek, Magda Bucholc, Diane P. Hanger, Charlotte James, Patrick A. Lewis, Ilianna Lourida, Wendy Noble, Francisco Rodriguez-Algarra, Jalil-Ahmad Sharif, Maria Tsalenchuk, Laura M. Winchester, Umran Yaman, Zhi Yao, Janice M. Ranson, David J. Llewellyn

Summary: This article reviews the application of artificial intelligence (AI) and machine learning (ML) in dementia research. The challenges of reproducibility and cross-species translation are discussed, and the potential of AI and ML methods to enhance research and translation is evaluated. Data resources and AI approaches are highlighted as solutions, and the exciting future possibilities of multi-omics analysis with AI in drug discovery are mentioned.

ALZHEIMERS & DEMENTIA (2023)

Article Clinical Neurology

Bridging integrator 1 protein loss in Alzheimer's disease promotes synaptic tau accumulation and disrupts tau release

Elizabeth B. Glennon, Dawn H. W. Lau, Rebecca M. C. Gabriele, Matthew F. Taylor, Claire Troakes, Sarah Opie-Martin, Christina Elliott, Richard Killick, Diane P. Hanger, Beatriz G. Perez-Nievas, Wendy Noble

BRAIN COMMUNICATIONS (2020)

No Data Available